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The radiotherapeutic management of the region-
al lymph nodes (RLNs) for breast cancer patients 
remains important, but it is technically challenging. 
Traditional approach to treat supraclavicular (SC) 
fossa and axilla is the use of an anterior-posterior 
(AP, i.e., anterior SC fossa field) and posterior axil-
lary boost (PAB) field arrangement [1–3]. In other 
words, the majority of breast cancer patients with 
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nodal involvement were treated with SC field alone 
or in combination with a PAB field. The goal of 
a PAB field arrangement is to ensure complete dose 
coverage of SC fossa and levels I/II/III axilla [3]. 
The majority of dose is delivered through a SC field 
prescribed to the depth of maximum dose or 3-cm 
depth to cover SC fossa and level III axilla [3]. 
However, more lateral level I/II axilla have a deeper 
location in comparison with the SC nodes. There-
fore, sufficient dose may not be delivered to these 
regions. To ensure adequate coverage of level I/II 
axilla a PAB field is used.   
Nevertheless, there are considerable debates re-
garding the effectiveness of a PAB field. To date, 
several studies have investigated dosimetric aspects 
of the PAB field and reported that it may not be an 
optimal technique to treat level I/II axillary LNs, in 
particular in the new era of breast cancer radiother-
apy (RT) [1-4].  In addition, the effect of a PAB on 
lymphedema development in breast cancer patients 
remains incompletely understood. Lymphedema 
has an important effect on patient’s quality of life 
(QOL) [5, 6]. Taken together, it is, therefore, impor-
tant for radiation oncologists to clearly understand 
dosimetric and clinical aspects of a PAB field.  
Therefore, the objectives of this literature review 
were (1) to evaluate whether a PAB field is an op-
timal method to target SC and axillary LNs; and 
(2) to investigate whether the addition of a PAB 
increases the incidence of lymphedema. 
Materials and methods
Search strategy and selection criteria
PubMed database was used for the literature 
searching from January 1990 to December 2019 
using the following search terms: (Breast cancer 
radiotherapy) AND (“Posterior axillary boost” OR 
“Regional nodal irradiation” OR “Regional radio-
therapy”). The following selection criteria were 
adopted: 
• inclusion criteria: studies on human, specifically 
investigating the dosimetric and clinical aspects 
or clinical efficacy of a PAB, full-text published 
articles in English;
• exclusion criteria: review articles, animal studies, 
lack of relevant outcome data, non-English writ-
ten articles, editorials, commentaries, conference 
abstracts.
To select a full-text article for review, search 
results were screened based on title and abstract 
(Fig.  1). Outcomes were expressed as reported 
originally. However, meta-analysis and statistical 
analysis were not carried out because of the obvi-
ous heterogeneity of patient cohort in the selected 
articles and variation in the outcomes reported.
Figure 1. Flowchart for literature search
255 records identified through
database searching
255 records screended 
on the basis of title and abstract
16 articles included in systematic review
194 records excluded
45 records excluded61 full-text articles assessed
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results and discussion  
Study selection and study characteristics
Two-hundred and fifty-five potentially relevant 
articles were identified and screened for title and 
abstract. Sixty-one full-text articles were evaluated 
for eligibility. Of these, 45 articles were excluded 
after full-text reading. Finally, a total of 16 articles 
that met the inclusion criteria were included in this 
literature review, as displayed in Figure 1. Seven ar-
ticles have investigated dosimetric aspects of a PAB. 
The remaining 9 articles have determined whether 
the addition of a PAB field increases the risk of 
lymphedema. There were no randomized studies. 
Only 2 of 9 articles have prospectively reported 
the impact of a PAB on the risk of lymphedema 
development. Table 1 and 2 provide a summary of 
the characteristics of the included studies and their 
main outcomes.
Posterior axillary boost field
Historically, a PAB field was developed based 
on the fact that the axillary LNs are deeper than 
the SC LNs in the pre-computed tomography 
(CT) era [1]. On the other hand, if a SC field 
provides inadequate coverage of deep LNs owing 
to axillary node separation, then a PAB field may 
be used to assure optimal dose distribution in the 
mid-axillary area [3]. In some centers, a PAB field 
was added if there were gross extranodal spread 
of tumor, inadequate axillary dissection, positive 
axillary nodes, and axillary failure without previ-
ous history of irradiation [3, 8, 13]. The medial 
border of a PAB field is typically defined by 1.5 to 
2 cm of the lung. The lateral border is at the pos-
terior axillary fold; however, the posterior axillary 
fold is not a useful plain film or CT landmark. The 
inferior border will match the breast tangentials 
and superior border splits the clavicle.  Also, the 
gantry may be tilted 10-15 degrees to spare the 
trachea, esophagus, and spinal cord. Of note, if 
the medial PAB border is defined by 2 cm of lung, 
there is no need for a gantry tilt. The prescribed 
dose is such that the combination dose distribu-
tion ensures adequate coverage of nodal volumes. 
There is an overlap between the anterior SC field 
and the PAB field with the amount of overlap 
varying from one patient to another. The borders 
of a PAB field may be edited to block hot spots 
owing to overlap with a SC field. 
Dosimetric effect of posterior axillary 
boost field 
Table 1 summarizes studies on dosimetric as-
pects of the PAB field in axillary LNs irradiation. 
A deep understanding about the depths of the SC 
and axillary LNs is an important step to elucidate 
the necessity of a PAB. Studies have reported that 
the depth of the SC and axillary LNs varies widely 
[1, 8]. In a study based on CT data, Bentel et al. 
measured the maximum depth of the SC and ax-
illary LNs in 49 patients at the Duke University 
of Medical Center [1]. Furthermore, these authors 
determined the relationship between the SC and 
axillary LN depth and patient’s size represented by 
the AP diameter. The median of the SC LNs depth 
was 4.3 cm in a range from 2.4 to 9.5 cm. The depth 
of the axillary LNs ranged from 1.4 to 8 cm, with 
a median of 4.3 cm. It was observed that the axil-
lary LNs lie at approximately the same depth or 
shallower than the SC in most patients. The results 
of that study demonstrated that the dose to the 
axillary LNs was within ± 5% of the SC dose in 
53% of patients and was 90% or more of the dose 
delivered in the SC in 90% of patients, when an 
anterior 6-MV beam only was employed to treat 
both the SC and axillary LNs. Therefore, they con-
cluded that these results can obviate the need for 
a PAB field. As suggested by Bentel et al., the use 
of higher energy beams, an anterior beam only, or 
opposed fields may be reasonable when the SC and 
axillary LNs are deep [1]. Furthermore, a deeper 
prescription dose point can provide sufficient plan-
ning target volume (PTV) coverage for patients 
with deep nodal volumes, this, however, results in 
more intense hot spots. A concern regarding higher 
energy beam is potential underdosing of superficial 
LNs. When a high energy beam is employed, the 
placement of bolus on the SC region is necessary 
owing to the behavior of depth dose. Depth dose 
does not decrease in a linear fashion. As a result, the 
use of an anterior beam only is suboptimal in some 
cases. However, the anterior beam may be useful 
for selected patients with small separations. It is 
worthwhile to mention that patients with elevated 
separations that require high energy beams do not 
have superficial LNs.
In another study, Goodman et al. measured the 
depths of SC and level I-III axillary LNs relative to 
the anterior skin surface [8]. The median (range) 
depths of the SC and level I-III axillary LNs were 3.7 
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cm (2.1–7 cm), 4.9 cm (1–12 cm), 5.1 cm (2.5–11.6 
cm), and 3.2 cm (1.9–7.4 cm), respectively. In addi-
tion, these LNs were positioned well anterior to the 
midline. In fact, none of these nodes were posterior 
to the midline. Meanwhile, the dosimetric cover-
age of the SC and axillary LNs with standard breast 
tangents and nodal fields was assessed. As reported 
by Goodman et al., with the use of the standard 
radiation tangents 90% of the level I axillary LNs 
and up to 70% of level II axillary LNs received 95% 
of the prescribed dose to the breast [8]. The results 
showed that there was a considerable variation in 
the nodal groups present in the PAB field. In 6/55 
patients were no nodal groups were observed in 
the PAB field [8]. Although the results of the study 
by Goodman et al. [8] are in good agreement with 
a previous study by Bentel and colleagues [1], it 
should be kept in mind that the level I axillary LNs 
rarely were in the anterior field in the Goodman et 
al. study [8]. Consistent with their findings, Pierce 
et al. reported that the level I axillary LNs were in 
the tangential fields and the apex of the axilla (the 
infraclavicular region) was treated through the SC 
field. However, the level II axillary LNs were par-
tially covered in the SC field, and were often supple-
mented by a PAB field [19]. 
The PAB field provides a good coverage of the 
level I/II axillary LNs because these nodes are usu-
ally at a greater depth. Of note, in most of the pa-
tients, the PAB field results in a large high-dose 
region in the AP region of the axilla [2, 7, 9]. This 
is the most important drawback of this technique, 
as reported in several studies. To reduce and op-
timize excessive hot spots at the exit of the PAB 
field, several techniques have been introduced [2, 
7, 9]. The core concept of these techniques was to 
compensate the overlap with the PAB port. Partial 
transmission blocks (PTBs) were used to attenu-
ate the anterior field. Rajasekar et al. reported that 
there was 14-25% dose variation in the axilla when 
irradiated by an anterior field and a PAB field [7]. 
They suggested that using an appropriate PTB in 
the anterior SC field corresponding to the diverging 
PAB field can optimize these dose variations, with 
the fact that the axillary LNs are deeper than the SC 
LNs [7]. In another method, a customized compen-
sator was applied to minimize undesirable hot spots 
in the anterior region of the axilla [9]. Jephcott and 
colleagues showed that the use of an anterior field 
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lary LNs in adjuvant RT can provide a good PTV 
coverage, but it produced an excessive hot spot (> 
120%) in 90% of patients (9/10 patients) [9]. In an 
attempt to reduce hot spots, an anterior field with 
PAB field to the axilla with customized compensa-
tion of the AP beam (APcomp-PAB) was assessed. 
Using this new technique significantly reduced hot 
spots > 120% in all cases. Only in one case, was this 
new technique rejected owing to a high brachial 
plexus point dose. Also, the APcomp-PAB gave an 
adequate PTV coverage similar to an anterior field 
with PAB field [9]. However, the creation of PTBs 
and compensators is time-consuming and requires 
a mold room. Nowadays, three-dimensional (3D) 
printing technology can fabricate treatment and pa-
tient-specific devices [20]. Therefore, above-men-
tioned accessories can be generated by 3D print-
ing technology that results in reducing time and 
cost. However, the addition of compensators and 
PTBs can lead to complexity in treatment plan-
ning. Above-mentioned techniques also increase 
the scatter dose received by the contralateral breast, 
and require an interruption in daily treatment frac-
tion. It should be noted, however, that toxicity of 
increased scatter is not clinically relevant, especially 
since most compensation is electronic these days. 
Taken all together, these techniques are impractical 
for routine clinical use. 
In an attempt to eliminate these drawbacks, Her-
nandez et al. have introduced an optimized PAB 
technique [2]. This technique was mainly based 
on the PAB technique, but the anterior field was 
split into two fields: a standard anterior field and 
another anterior field with the same gantry angle 
that shielded the region of overlap with the PAB 
field to decrease the hot spots. The optimized PAB 
technique provided adequate coverage of the SC 
and axillary LNs while minimizing radiation dose 
to the surrounding normal tissues. Furthermore, 
this technique overcame the main disadvantage of 
the PAB technique, i.e., it reduced hot spots. The 
mean hot spot dose was 107.7% in the optimized 
PAB technique and 113.5% in the PAB technique 
(p = 0.006) [2]. 
Recent studies have indicated that the PAB field 
is a suboptimal technique for treating SC and ax-
illary LNs and new techniques such as intensity 
modulated RT (IMRT) can provide the opportu-
nity to optimize dose coverage and reduce radia-
tion-induced damage to the surrounding healthy 
tissues [3, 4]. The results of the study by Wang et 
al. showed that CT-based techniques such as an 
SC field with an anterior boost field and IMRT 
resulted in superior dose coverage compared with 
PAB field [3]. In addition, superior lung sparing 
and dose conformity to the target were achieved 
by the IMRT technique. Authors also indicated 
that the use of the anterior axillary boost (AAB) 
field resulted in producing smaller hot spots (i.e., 
105% isodose) compared with the PAB field [3]. 
The mean the treatment volume receiving 105% 
or greater of the prescribed dose (V105%) was 
55.9 cc for an AAB field and 70.0 cc for the PAB 
technique (p = 0.037). Of note, the PAB tech-
nique was not based on CT data, whereas the AAB 
technique was a CT-based treatment planning. 
In contrast, when both techniques were based on 
individual patient’s anatomy, the AAB technique 
generated higher and larger hot spots; therefore, 
it is dosimetrically inferior compared to the PAB 
field, as reported by Hernandez and colleagues 
[2]. In another study, Sethi et al. compared several 
3D techniques and IMRT for level III axillary LNs 
and SC LNs coverage [4]. Prone IMRT technique 
resulted in adequate nodal PTV coverage, and 
reduced ipsilateral lung V20. The results of that 
study revealed that a supine four-field 3D confor-
mal RT (3DCRT) using PAB resulted in an average 
of only 59% of the LN-PTV receiving 100% of the 
prescribed dose [4]. Bentel et al. thought that cov-
ering LNs with 90% of the dose was good enough 
to justify omitting PAB [1]. In the study by Sethi 
et al., the PAB technique was criticized for cover-
ing only 59% of the PTV with 100% of the dose 
[4]. Coverage by 100% of the prescription dose is 
nonstandard. 
impact of posterior axillary boost field  
on lymphedema
For breast cancer survivors, lymphedema is con-
sidered as one of the most important, physically 
and emotionally, morbidities after surgery, RT, and 
taxane-based chemotherapy. It has been globally 
demonstrated that lymphedema has a significant 
negative impact on patients’ QOL [5, 6]. Recent-
ly, several studies have been conducted to deter-
mine independent predictors of lymphedema after 
breast RT [15, 16, 21]. A PAB field is considered as 
a potential RT risk factor for lymphedema. To date, 
several studies have been conducted to quantify 
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whether the addition of a PAB field can increase the 
risk of lymphedema, as outlined in Table 2 [10–18].
It has been shown in some studies that patients 
with a PAB field have an increased risk of lymph-
edema [11, 12, 14]. Researchers from Massachu-
setts General Hospital retrospectively evaluated the 
risk factors of lymphedema in 727 stage I–II breast 
cancer patients treated with breast conservation 
therapy [11]. The 10-year actuarial incidence of 
lymphedema was 4.1%. Their data suggest that re-
gional node irradiation (RNI) is the only significant 
risk factor for lymphedema, with a 10-year risk of 
lymphedema from breast-only RT of 1.8% vs. 8.9% 
for RNI (p = 0.001). In that study, the subgroup re-
ceiving a SC field alone (three-field technique) was 
small. Therefore, these patients were grouped with 
SC + PAB field patients (four-field technique). Be-
cause most patients were treated with the four-field 
technique, it is difficult to estimate accurately 
whether the addition of a PAB field increased the 
risk of lymphedema compared with a SC field alone 
[11]. A study from of Roswell Park has revealed that 
the addition of a PAB field increased lymphedema 
risk [12]. Hinrichs et al. investigated predictors of 
lymphedema secondary to post-mastectomy RT in 
105 patients [12]. They found that the addition of 
a PAB field doubled the rate of lymphedema from 
nearly 23% to 47% (p = 0.047). Moreover, their 
data indicated that RT dose, overlapping the RT 
technique, RT before 1999, and RT at Roswell Park 
also were significant predictors of lymphedema. Of 
note, although SC, internal mammary, mastectomy 
scar boost, and chest wall tangential photon beam 
radiation increased the risk of lymphedema, these 
differences were not statistically significant [12]. In 
a retrospective study, Bar Ad et al. evaluated the risk 
factors for progression of lymphedema after breast 
cancer conversation therapy in 266 stage I-II breast 
cancer patients at the Hospital of the University of 
Pennsylvania [14]. The results of univariate Cox 
models indicated that treatment of the SC nodal re-
gion (p = 0.035) and the use of PAB (p = 0.014) were 
remarkable risk factors for progression of lymph-
edema. There was no statistically significant differ-
ence in arm lymphedema progression between the 
patients treated with B + SC and B-only (p = 0.4), 
but patients treated with B + SC + PAB were in 
greater risk of lymphedema, as compared with pa-
tients treated with B-only irradiation (p = 0.01) 
[14]. The freedom from progression at 5 years of 
follow-up was 73% for patients treated with B-only 
irradiation and 36% for patients receiving RT to 
B + SC + PAB [4].  
In contrast, Chua et al. have compared the 
lymphedema rates between SC-only RT and 
SC + PAB RT, reporting no significant difference 
in the rate of lymphedema [10].  From their data it 
can be seen that the rate of lymphedema was 40% (6 
of 15 patients) in the SC field alone, and 31% (42 of 
136 patients) in the SC + PAB field group. It should 
be noted that 10 of 136 patients who experienced 
severe lymphedema were in the SC + PAB group, 
no severe lymphedema was found in the SC-only 
group [10] Hayes et al. quantified well the risk of 
lymphedema from RNI in a series of 2,579 breast 
cancer patients [13]. In their study, patients were 
treated with three different radiation fields setting, 
2,169 patients (84%) received radiation to the breast 
(B), 226 patients (8.8%) to the breast and SC LNs 
(B + SC), and 184 patients to the breast, SC LNs and 
a PAB (B + SC + PAB). Overall, lymphedema was 
observed in 18% of patients at median follow-up of 
81 months. The risk of lymphedema was 16%, 23%, 
and 31% in the B-only, B + SC, and B + SC + PAB 
group, respectively. The rate of lymphedema in the 
B + SC + PAB group was comparable with the 47% 
incidence of lymphedema found by Hinrichs et al. 
with the addition of a PAB. In addition, the results 
for the N1 subgroup showed that the adding a PAB 
over tangents led to an increase in the risk of lymph-
edema (p = 0.0017), but there was no statistically 
significant increase in lymphedema risk by adding 
a PAB to B + SC RT (p = 0.8002). In the N2 sub-
group, the addition of a PAB increased the risk of 
lymphedema 4.5 fold over B + SC RT (p = 0.0011). 
Meanwhile, there was no statistically significant dif-
ference in the breakdown of nodal failures among 
the three groups (p = 0.35) [13]. Although the study 
by Hayes et al. had several main strengths, such as 
the large sample size and the systematic analysis of 
all potential lymphedema risk factors, retrospective 
nature of the study and extensive LN dissection or 
the number of positive LNs can be great risk factors 
for developing lymphedema owing to the interfer-
ence of lymphatic drainage irrespective of RT field 
arrangement. 
A study from William Beaumont Hospital evalu-
ated the rates of breast cancer-related lymphedema 
in 1497 patients treated with whole-breast irradia-
tion [15].  RT parameters were analyzed in patients 
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with and without lymphedema. The data from that 
study indicated that the addition of regional irra-
diation (i.e., SC, PAB, and internal mammary field) 
over whole breast irradiation did not statistically 
significantly increase the incidence of lymphedema. 
The findings showed that adding a PAB field ap-
proximately doubled the actuarial rate of lymph-
edema, but it was no statistically significant (14.7% 
with PAB vs. 7.3% without PAB, p = 0.10) [15]. 
Consistent with Hayes et al. study [13], in a pro-
spective single-institution cohort study, Warren et 
al. determined that the addition of a PAB to SC 
field did not increase the risk of lymphedema in 
comparison with SC alone [16]. No statistically 
significant difference in lymphedema risk between 
SC and SC + PAB was observed (p = 0.96). These 
findings also were in good agreement with a prior 
study by Chua et al. [10]. However, Warren et al. 
found that the addition of RLN radiation, regard-
less of radiation field type (i.e. SC or SC + PAB), 
compared with breast/chest wall radiation alone 
significantly increased the risk of lymphedema 
with a hazard ratio of 1.7 (p = 0.025) [16]. Con-
sistent with Warren et al. study, Graham et al. also 
reported that using axillary irradiation results in 
a significant increase in the lymphedema rates 
whether defined by using a PAB field (p = 0.004) 
or subdivided by any irradiation lateral to the cora-
coid (p = 0.002) [22]. In another report, dosimetric 
risk factors for the incidence of lymphedema in 
172 breast cancer patients treated with RNI radia-
tion at the Massachusetts General Hospital were 
analyzed [17]. The 2-year cumulative incidence of 
lymphedema was 22.27% and 20.98% for SC and 
SC + PAB, respectively. Meanwhile, RLN radiation 
field type was not associated with the development 
of lymphedema (p = 0.66 for SC vs. SC + PAB 
field). In addition, there was no relationship either 
between lymphedema risk and other specific RT 
parameters such as fraction size, extent of humeral 
head, beam energy, and breast tangent type [17]. It 
should be noted that the vast majority of patients 
with lymphedema received axillary LN dissec-
tion (87%) [17], a well-documented risk factor for 
lymphedema development [23]. This, along with 
a relatively small sample size (n = 172) can obscure 
the impact of the independent RT risk factor on 
the development of lymphedema.   
As reported by Hayes and colleagues, in patients 
with 4-9 positive LNs (N2 subgroup, n = 109) that 
most often undergo RNI, although the SC field did 
not increase the risk of lymphedema in compari-
son with tangents, the use of a PAB field increased 
lymphedema risk 4.5 fold over tangents and a SC 
[13]. In this subgroup of patients, this strong cor-
relation resulted in a fall of the number of LNs 
dissected [13].  As a result, it is necessary to avoid 
a PAB unless there are absolute indications for its 
application. It is clear that the rate of nodal recur-
rence in the PAB group is lower than in the B-only 
or B + SC group (18/2169 patients in the B group, 
8/226 patients in the B + SC group, and 2/184 pa-
tients in the B + SC + PAB group) [13]. However, 
studies have not demonstrated the advantage of 
a PAB radiation in improving nodal control. Of 
note, one possible reason for decreasing nodal re-
currence in the PAB group may be associated with 
developed metastatic disease in these patients that 
results in ceasing time surveillance for nodal recur-
rences.
As mentioned above, previous reports investigat-
ed differences in radiation beam arrangement, i.e., 
adding a PAB field, but did not clearly determine 
the volume of axillary tissue irradiated. On the oth-
er hand, field designs may be more important for 
the incidence of lymphedema than field arrange-
ment [18]. A recent study by Gross et al. has docu-
mented the relationship between RT field design 
and lymphedema development [18]. A cohort of 
492 patients with stage II-IV breast cancer who had 
received RLN radiation following breast surgery 
were divided into three subgroups according to dif-
ferent radiation fields. Group 1 (n = 101) received 
a SC field that excluded the uppermost portion of 
the level I/II axilla but could include a PAB field, 
group 2 (n = 202) received radiation to the major-
ity of the level I to III of the axilla with or without 
PAB, and group 3 (n = 189) received radiation to 
the entirety of the anterior and posterior axilla. On 
the other hand, no patients in group 3 treated were 
with a PAB field, while more patients in group 2 
received a PAB field when compared with group 
1, as the control group. The 5-year lymphedema 
rates in group 2 (37.1%) and group 3 (36.7%) were 
significantly higher than those in group 1 (7.7%, 
p < 0.0001), despite the fact that more of these pa-
tients had undergone sentinel LN biopsy (15–19% 
vs. 6%) when compared with patients in group 1. Of 
note, the likelihood of the development of lymph-
edema after sentinel LN biopsy is lower than axil-
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lary LN dissection. The incidence of lymphedema 
at 12 months was 11% after axillary LN dissection 
and 6% after sentinel LN biopsy in the American 
College of Surgeons Oncology Group Trial Z0011 
[24].  Gross et al. suggest that the lateral border of 
the 2D nodal RT, as a proxy for the volume of tissue 
irradiated, is a significant factor for lymphedema 
development [18]. In other words, radiation of the 
upper level I to II axilla appears to be particularly 
important for the development of lymphedema risk 
after axillary dissection.   
As observable in above-mentioned studies, the 
impact of a PAB RT on the development of lymph-
edema is controversial. A possible source of these 
controversies can be the fact that it was unknown 
what degree of the upper axilla was treated with 
RNI. As described by Gross et al., radiation field 
design can result in increasing radiation to the 
volume of axillary tissues, thereby increasing the 
incidence of lymphedema [18], whereas other pre-
vious studies focused on radiation field arrange-
ment. Besides, a recent study has identified that 
dose delivered to the axillary-lateral thoracic ves-
sel juncture (ALTJ, the area superior to axillary 
level I) can be associated with lymphedema risk 
[25]. As a consequence, radiation field design can 
be a more relevant risk factor for development 
of lymphedema than radiation field arrangement. 
Another issue of possible relevance for the impact 
of a PAB field on the incidence of lymphedema is 
the lack of uniformity in measuring lymphedema. 
As outlined in Table 2, investigators have used 
multiple metrics to quantify and qualify the inci-
dence of lymphedema, including perometry, arm 
circumference, etc. Therefore, standardizing the 
method of detecting lymphedema is needed. The 
testing of the inclusion of upper arm lymphatics 
in the regional LN irradiation target volume, and 
universal methodology measuring lymphedema 
are all areas for possible future studies. Besides, as 
observable in Table 2, most studies were retrospec-
tive and, therefore, may suffer from underestimat-
ing actual incidence of lymphedema owing to the 
lack of documentation in medical record, delayed 
onset, etc. Moreover, retrospective studies have 
higher potential sources of bias and confound-
ing. These are issues that will require additional 
investigation before definitive recommendations 
can be made regarding the therapeutic index of 
a PAB radiation. 
conclusion 
There are few studies that have investigated 
whether a PAB is necessary for RLNI. A key fac-
tor in using a PAB is the depth of axillary LNs that 
today is well determined on the basis of CT. The 
results of this literature review show that depending 
on dose distribution and patient’s anatomy, a PAB 
field is employed to supplement axillary dose. The 
PAB field provides a good coverage of level I/II 
axillary LNs because these LNs are located much 
deeper. The most important concern regarding 
a PAB is that it produces a large high-dose region 
in the AP region of the axilla. To reduce drawbacks 
of a PAB field RT, physicists and radiation oncolo-
gists should optimize and develop a traditional PAB 
field, as suggested by Jephcott et al. [9] and Her-
nandez et al. [2]. IMRT technique can also provide 
excellent dose coverage and simultaneously reduce 
radiation-induced normal tissue toxicity. However, 
the use of IMRT techniques involves higher com-
plexity in treatment planning and delivery steps 
and, therefore, they are not commonly used for the 
SC and axillary LNs irradiation. Moreover, pro-
spective trials are needed to clarify the efficacy of 
this approach. 
On the one hand, a recent study has suggest-
ed that volume and distribution of axillary irra-
diation may be the most important risk factors of 
lymphedema development compared with beam 
arrangement alone. On the other hand, in studies 
where beam arrangement was investigated, there 
are conflicting reports on the association of a PAB 
field with the incidence of lymphedema. Although 
data reveal that the addition of RNI to breast ir-
radiation significantly increases the risk of lymph-
edema in patients with breast cancer, prospective 
studies and the vast majority of retrospective stud-
ies have reported the use of a PAB RT does not 
result in a statistically significant increase in the 
risk of lymphedema development over SC-alone 
RT. Of note, there is a trend of increasing risk of 
lymphedema with a PAB field. Therefore, clinicians 
should continue to weigh lymphedema risk in in-
dividual patients against the benefit of a PAB, in 
particular after axillary dissection. In the light of 
these findings, although definitive recommenda-
tions regarding the clinical benefit of a PAB field 
are relatively difficult, axillary radiation with a PAB 
field is recommended for targeting level I/II axilla 
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if there are clinically matted LNs, ≥ 4 involved axil-
lary LNs, gross extranodal spread of tumor, all LNs 
dissected positive, positive sentinel LNs without 
a subsequent completion axillary dissection, an in-
adequate axillary dissection (< 6 LNs), or the high-
est LNs dissected being positive [3, 13]. 
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